Abstract
Background and Objective: Asenapine is an atypical antipsychotic approved by US Food and Drug Administration in 2009 and by European Medicines Agency in 2010 for Schizophrenia and Bipolar Disorder treatment. Currently, many studies have been developed in an attempt to clarify and minimize the risks related to the use of psychotropic during pre/postnatal period on patients with a history of mental disorders.
Conclusion: The aim of this study was to test the impact of pre and/or postnatal exposition to asenapine on mice offspring behavior. Four groups of animals, previously treated with a dosage equivalent to 50% of the bioavailability obtained with a 20 mg daily use for human treatment, were exposed to the Open Field and Elevated plus Maze test. Only the group exposed to asenapine during both pre and postnatal periods showed response difference in the Elevated Plus Maze test, which was restricted to urination. However, our data suggest that the administration of asenapine does not induce significant anxiety-like behaviors in mice.
Keywords: Antipsychotic, schizophrenia, bipolar disorder, behaviour, anxiety, stress, open field, elevated plus maze.
Graphical Abstract
CNS & Neurological Disorders - Drug Targets
Title:Systemic Administration of Antipsychotic Asenapine Pre or Postnatal does not Induce Anxiety-like Behaviors in Mice
Volume: 16 Issue: 10
Author(s): Thais Barbosa de Souza, Daniela Miranda Farias, Rozimeri Fatima Coletti, Maria Silvia Oliveira, Carolina Gomes Carrilho, Jorge Aparecido de Barros, Susana Elisa Moreno, Eric Murillo-Rodriguez, Sergio Machado and Andre Barciela Veras*
Affiliation:
- Intercontinental Neuroscience Research Group, Campo Grande,Brazil
Keywords: Antipsychotic, schizophrenia, bipolar disorder, behaviour, anxiety, stress, open field, elevated plus maze.
Abstract: Background and Objective: Asenapine is an atypical antipsychotic approved by US Food and Drug Administration in 2009 and by European Medicines Agency in 2010 for Schizophrenia and Bipolar Disorder treatment. Currently, many studies have been developed in an attempt to clarify and minimize the risks related to the use of psychotropic during pre/postnatal period on patients with a history of mental disorders.
Conclusion: The aim of this study was to test the impact of pre and/or postnatal exposition to asenapine on mice offspring behavior. Four groups of animals, previously treated with a dosage equivalent to 50% of the bioavailability obtained with a 20 mg daily use for human treatment, were exposed to the Open Field and Elevated plus Maze test. Only the group exposed to asenapine during both pre and postnatal periods showed response difference in the Elevated Plus Maze test, which was restricted to urination. However, our data suggest that the administration of asenapine does not induce significant anxiety-like behaviors in mice.
Export Options
About this article
Cite this article as:
de Souza Barbosa Thais , Farias Miranda Daniela , Coletti Fatima Rozimeri , Oliveira Silvia Maria , Carrilho Gomes Carolina, de Barros Aparecido Jorge , Moreno Elisa Susana, Murillo-Rodriguez Eric , Machado Sergio and Veras Barciela Andre *, Systemic Administration of Antipsychotic Asenapine Pre or Postnatal does not Induce Anxiety-like Behaviors in Mice, CNS & Neurological Disorders - Drug Targets 2017; 16 (10) . https://dx.doi.org/10.2174/1871527317666171213162403
DOI https://dx.doi.org/10.2174/1871527317666171213162403 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Fighting Against Alzheimer's Disease: Synthesis of New Pyrazoline and Benzothiazole Derivatives as New Acetylcholinesterase and MAO Inhibitors
Letters in Drug Design & Discovery Systemic DNA Damage Response and Metabolic Syndrome as a Premalignant State
Current Molecular Medicine Biomarkers for Alzheimer’s Disease
Current Alzheimer Research Silymarin Extends Lifespan and Reduces Proteotoxicity in C. elegans Alzheimer’s Model
CNS & Neurological Disorders - Drug Targets Transendothelial Migration of Monocytes: The Underlying Molecular Mechanisms and Consequences of HIV-1 Infection
Current HIV Research Management of the Menopausal Disturbances and Oxidative Stress
Current Pharmaceutical Design Lactoferrin: A Biologically Active Molecule for Bone Regeneration
Current Medicinal Chemistry Epidemiology and Etiology of Alzheimer’s disease: From Genetic to Non- Genetic Factors
Current Alzheimer Research Non-Amyloid PET Imaging Biomarkers for Neurodegeneration: Focus on Tau, Alpha-Synuclein and Neuroinflammation
Current Alzheimer Research Melatonin, Autophagy and Intestinal Bowel Disease
Current Pharmaceutical Design In silico Modeling Studies of 5-HT2B Antagonistic Activity of 2-(2- phenylethyl)chromone Derivatives from Cucumis melo Seeds
Letters in Drug Design & Discovery Current Approaches for the Treatment with Thyroid Hormone Analogs
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) A Friend in Need May Not be a Friend Indeed: Role of Microglia in Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets PET Tracers for Serotonin Receptors and Their Applications
Central Nervous System Agents in Medicinal Chemistry Retinal Degenerations: From Cell Signaling to Cell Therapy; Pre-Clinical and Clinical Issues
Current Gene Therapy Relevance of Dopamine D2/Neurotensin NTS1 and NMDA/Neurotensin NTS1 Receptor Interaction in Psychiatric and Neurodegenerative Disorders
Current Medicinal Chemistry GDNF Family Ligands: A Potential Future for Parkinson's Disease Therapy
CNS & Neurological Disorders - Drug Targets Cancer Stem-Cells Patents in the Context of their Therapeutic Purposes: Exploring the Latest Trends (2011-2015)
Recent Patents on Regenerative Medicine Commentary((Research Highlights)(Amyotrophic Lateral Sclerosis: Targeting the Body’s Energy Engine))
CNS & Neurological Disorders - Drug Targets Applications of Exosomes in Targeted Drug Delivery for the Treatment of Parkinson’s Disease: A Review of Recent Advances and Clinical Challenges
Current Topics in Medicinal Chemistry